Breakthrough in Understanding PTP1B's Role in Tumor Immunogenicity
Researchers at the National University of Singapore (NUS) have made a groundbreaking discovery by identifying protein tyrosine phosphatase 1B (PTP1B), an enzyme residing in the endoplasmic reticulum (ER) of cells, as a critical regulator of immunogenic cell death (ICD) in cancer. This finding, detailed in a recent study published in the Journal of the American Chemical Society (JACS), reveals how targeting PTP1B can transform non-immunogenic cancer cell death into a powerful immune-stimulating event, significantly enhancing the effectiveness of cancer immunotherapy.
ICD is a specialized form of regulated cell death that not only kills tumor cells but also alerts the immune system, exposing 'eat-me' signals like calreticulin on the cell surface to trigger phagocytosis by dendritic cells and macrophages. These antigen-presenting cells then activate cytotoxic T cells, providing long-term protection against tumor recurrence. Traditional chemotherapies often induce non-immunogenic death, limiting their synergy with immunotherapies like PD-1 inhibitors. The NUS team's platinum-based compounds, Pt-NHC and PlatinER (Pt-ER), bypass this by inducing Type II ICD via ER stress, directly linking to PTP1B inhibition.
The Science Behind PTP1B and Its Inhibition
PTP1B, encoded by the PTPN1 gene, is a protein tyrosine phosphatase that removes phosphate groups from tyrosine residues on proteins, negatively regulating signaling pathways involved in cell proliferation, metabolism, and immune responses. In cancer cells, PTP1B dampens ER stress responses by inhibiting PERK (protein kinase R-like ER kinase), a key sensor in the unfolded protein response (UPR). This suppression prevents surface exposure of calreticulin (ecto-CRT), HMGB1 release, and ATP secretion—hallmarks of ICD.
The NUS researchers employed sophisticated chemical biology tools: photoactivatable probes derived from Pt-ER underwent photoaffinity labeling, followed by click chemistry, pull-down, and tandem mass tag (TMT) quantitative proteomics. This pinpointed PTP1B as the top-enriched target. Confirmation came via cellular thermal shift assay (CETSA) showing direct binding, enzymatic inhibition assays (IC50 ~20 μM), confocal microscopy for colocalization, and siRNA knockdown replicating ICD enhancement. In mouse models using CT26 colorectal tumors, vaccination with Pt-ER-treated cells yielded 60% tumor-free survival upon rechallenge, far surpassing controls.
- Pt-ER binds PTP1B in mitochondria-associated ER membranes, blocking phosphatase activity.
- PTP1B knockdown activates PERK, boosting ecto-CRT by 2-3 fold and phagocytosis by 50%.
- Pharmacological inhibitors like DPM-1001 mimic effects, confirming specificity.
Bioinformatics across TCGA datasets showed PTP1B overexpression correlates with poor prognosis in colorectal adenocarcinoma (COAD), breast invasive carcinoma (BRCA), and others, plus inverse links to T-cell infiltration.
Overcoming Challenges in Cancer Immunotherapy
Cancer immunotherapy, harnessing the patient's immune system via checkpoint inhibitors or CAR-T cells, achieves durable responses in 20-40% of patients but fails in 'cold' tumors lacking immunogenicity. In Asia, including Singapore, colorectal cancer ranks among top malignancies, with 5-year survival ~60-70%, lagging behind Western rates due to late diagnosis and limited immunotherapy efficacy. PTP1B inhibition addresses this by converting immunologically silent cell death into ICD, priming tumors for immune attack and synergizing with PD-1 blockade.
Singapore's National Cancer Centre reports rising colorectal cases, projected 20% increase by 2030, underscoring urgency. NUS's work aligns with national RIE2025 plan investing S$25B in biomedical sciences, positioning local universities as global leaders.Related international collaborations boost such research.
NUS Team's Innovative Methods and Experimental Validation
Led by Prof. ANG Wee Han from NUS Chemistry, the interdisciplinary team—including postdocs Jiao Xia Zou and Pavel Ivanov-Rostovtsev—integrated synthetic chemistry with proteomics. They synthesized light-activated probes (P-1, P-2b, P-3) to capture ER targets, identifying PTP1B via mass spec (enrichment >10-fold). Step-by-step validation:
- Treat CT26 cells with Pt-ER, confirm ICD markers (flow cytometry for ecto-CRT, ELISA for HMGB1/ATP).
- Probe irradiation, click pulldown, TMT-LC-MS/MS analysis (PTP1B top hit).
- CETSA: Pt-ER stabilizes PTP1B thermal stability.
- siPTP1B: Mirrors Pt-ER effects; PERK inhibitor restores suppression.
- In vivo vaccination: 4x10^6 treated cells immunize BALB/c mice, rechallenge shows protection.
These rigorous approaches set a benchmark for target deconvolution in ICD research.
Implications for Colorectal Cancer Treatment in Singapore
Colorectal cancer, Singapore's third most common, affects ~3,000 annually, with immunotherapy response rates ~15% for MSI-high subsets. PTP1B's role in suppressing T-cell infiltration and ER stress offers a combinatorial strategy: Pt-ER + anti-PD-1 could 'heat up' cold tumors. Public datasets confirm PTP1B's prognostic value, high expression linking to low immune scores.
Clinically, small-molecule PTP1B inhibitors (e.g., from prior diabetes research) could repurpose for oncology, reducing resistance. NUS's findings pave for trials, aligning with Singapore's Phase III+ focus via A*STAR and NUHS.NUS Science Faculty announcement
Broader Applications and Future Directions at NUS
Beyond colorectal, PTP1B influences breast, liver cancers; its dual role in tumor cells (proliferation) and T-cells (negative regulation) suggests pan-cancer potential. Prof. Ang notes: "Next steps include structural studies of PlatinER-PTP1B interaction via molecular dynamics." NUS plans pharmacokinetics, toxicity profiling, and combos with existing therapies.
In Singapore's ecosystem, this bolsters Yong Loo Lin School of Medicine's immuno-oncology hub, attracting talent. For aspiring researchers, crafting a strong academic CV is key to joining such labs.
Singapore's Leadership in Biomedical Research
NUS ranks top 10 globally in chemistry/pharmacy (QS 2026), driving Singapore's biotech hub status with S$1B+ annual R&D. This PTP1B work exemplifies translational impact, from bench to bedside, amid Asia's immunotherapy surge despite access barriers.
Challenges like high costs (immunotherapy ~S$100K/course) persist, but discoveries like this promise affordable platinum combos. Explore Singapore higher ed opportunities for cutting-edge roles.
Stakeholder Perspectives and Global Context
Prof. Ang emphasizes: "PTP1B links platinum ICD inducers to immune effects." Oncologists hail potential for 'cold-to-hot' tumor conversion. Globally, PTP1B inhibitors in trials (e.g., Compound-182 for T-cell boost) validate NUS findings.Duke-NUS complements with related advances.
Impacts: Reduced relapse, personalized therapy via PTP1B biomarkers. Future: AI-driven inhibitor design at NUS.
Photo by National Cancer Institute on Unsplash
Career Insights in Cancer Research at Singapore Universities
This discovery highlights demand for chemists, immunologists at NUS. Research jobs in immunotherapy proliferate, with postdocs earning S$60K+. Advice: Gain proteomics experience; network via Rate My Professor. Singapore's ecosystem offers postdoc success tips.
Outlook: Transforming Cancer Care Through PTP1B Targeting
NUS's PTP1B revelation heralds a new era in chemoimmunotherapy, promising higher response rates for Asian patients. With ongoing trials and collaborations, expect clinical translation by 2030. Stay updated via university jobs, higher ed jobs, career advice, and professor ratings to join the revolution.